Program
TQB6411
A development code. Also written as “TQB6411 Injection”, “TQB6411 for Injection” and “TQB6411 injection”.
In Sino Biopharmaceutical's pipeline, EGFR/c-Met ADC
. Its studies are mostly in Esophageal Neoplasms · Lung Neoplasms, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 33 open or running | phase 2since Jan 16, 2026 | Jun 20, 2025 | Feb 2027phase 2 · NCT07367516 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB6411
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 20, 2025First study: phase 1 study in Advanced Malignant TumorsFirst studyNCT07043751 · 216 planned · China
- Jan 16, 20262 phase 2 studiesPhase 2 reachedNCT07367529, NCT07367516
Ahead
- Feb 2027Primary completion: phase 2 study in Esophageal NeoplasmsNCT07367516
- Dec 2027Primary completion: phase 1 study in Advanced Malignant TumorsNCT07043751
- Dec 2028Primary completion: phase 2 study in Advanced Lung CancerNCT07367529
TargetBeta
“EGFR/c-Met ADC”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 5 |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 1 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07367516Esophageal Neoplasms · China | 2 | Recruiting | Feb 2027 | 105 |
| NCT07367529Advanced Lung Cancer · China | 2 | Recruiting | Dec 2028 | 465 |
| NCT07043751Advanced Malignant Tumors · China | 1 | Recruiting | Dec 2027 | 216 |
How it is read
Names in the registry
- “TQB6411 Injection”, 1 entry
- “TQB6411 for Injection”, 1 entry
- “TQB6411 injection”, 1 entry
Codes read as this program: TQB6411.
Conditions, from the studies’ own filings
- Esophageal Neoplasms, 1 study
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.